Results 111 to 120 of about 3,645,426 (307)

FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects

, 2023
Cancer immunotherapy has been extensively investigated in lymphoma over the last three decades. This new treatment modality is now established as a way to manage and maintain several stages and subtypes of lymphoma.
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Kamal Al-Rabi, Malik E. Juweid, Hikmat Abdel-Razeq, Mohammad Ma’koseh, Asem Mansour   +6 more
core   +1 more source

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Journal of Translational Medicine, 2017
Background Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.
Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio M. Grimaldi, Aldo Pinto, Paolo Antonio Ascierto   +8 more
doaj   +1 more source

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

FEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim, Marco Corazzari, Iman Osman, Jane Armstrong, Noel Carter   +4 more
wiley   +1 more source

The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers

, 2022
As the indications for the use of immunotherapy in genitourinary malignancies expand, its role in combination with standard or conventional therapies has become the subject of contemporary studies.
Isabella Dolendo, Rana R. McKay, Aditya Bagrodia, Ava Saidian, Amirali Salmasi, Brent Rose, Andrew Sharabi, Tyler F. Stewart   +7 more
core   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

MANIFEST:Multiomic platform for cancer immunotherapy [PDF]

Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-changing drug-induced ...
Hubank, M, Waddell, T, Lim, Kok Haw Jonathan; id_orcid, Dive, Caroline, Szabados, B, Stares, Mark, Strange, Amy, Corrie, Pippa G, Lawley, Trevor D, Turajlic, Samra, Turajlic, S, Waddell, Tom, Corrie, PG, Strange, A, Symeonides, SN, Zelenay, S, Larkin, James, Lawley, TD, Tippu, Zayd, MANIFEST consortium, Tippu, Z, Lim, KHJ, Hubank, Michael, Salto-Tellez, Manuel, Szabados, Bernadett, Turner, NC, Zelenay, Santiago, Stewart, GD, Stewart, Grant D, Stares, M, Larkin, J, Dive, C, Salto-Tellez, M, Turner, Nicholas C, Symeonides, Stefan N, Corrie, P. G., Lawley, T. D., Zelenay, S., Turajlic, S., Lim, K. H. J., Waddell, T., Salto-Tellez, M., Larkin, J., Strange, A., Hubank, M., Symeonides, S. N., Tippu, Z., Turner, N. C., Dive, C., Stewart, G. D., Stares, M., Szabados, B.   +51 more
core   +1 more source

Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough.

, 2021
Abundant neoantigens are considered responsible for the immunotherapy sensitivity of mismatch repair-deficient (MMRd) cancers. In this issue of Cancer Cell, two papers show that MLH1 mismatch repair gene loss promotes cGAS-STING activation, interferon ...
Gerlinger, M, Marco Gerlinger
core   +1 more source

Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis

Blood Advances
: Chronic graft-versus-host disease (GVHD) is less frequent after posttransplant cyclophosphamide (PTCy)–based prophylaxis, but its clinical characteristics and outcomes compared with chronic GVHD after non-PTCy approaches remain understudied.
Joseph Pidala, Jongphil Kim, Jose Laborde, Samantha Knott, Krishnakar Mogili, Justin Zinn, Alicia Monroe, Rawan Faramand, Reshma Ramlal, Farhad Khimani, Doris K. Hansen, Nancy Torres-Luna, Michael D. Jain, Lia E. Perez, Asmita Mishra, Nima Ghalehsari, Omar Castaneda-Puglianini, Melissa Alsina, Fabiana Perna, Michael Nieder, Abu-Sayeef Mirza, Hien Liu, Taiga Nishihori, Alaa Ali, Deepak Chellapandian, Frederick L. Locke, Nelli Bejanyan, Claudio Anasetti, Aleksandr Lazaryan   +28 more
doaj   +1 more source

Immunotherapy in cancer

Seminars in Arthritis and Rheumatism
Immunotherapy has revolutionized the treatment of cancer. However, therapy resistance and immune mediated side effects reduce the overall success. Recent developments in these two areas were reported at the 2024 ATT conference. Here we discuss that immunotherapy resistance relies on immune escape mechanisms of cancer cells.
openaire   +2 more sources

Immunotherapy for Bladder Cancer [PDF]

Klinicka Onkologie, 2017
Urothelial carcinoma is the most common urological malignancy. Nonspecific immunotherapy using the Bacillus Calmette-Guerin vaccine has long been the mainstay for the treatment of high-risk superficial bladder carcinoma in an adjuvant setting after transurethral endoscopic resection.
openaire   +2 more sources